Literature DB >> 5645860

Inhibition of Hageman factor activation.

H L Nossel, H Rubin, M Drillings, R Hsieh.   

Abstract

A method for studying inhibitors of the contact stages of blood coagulation is described. A number of positively charged substances were shown to inhibit the contact stages. The inhibitory substances include spermine, cytochrome c, ribonuclease, and lysozyme. The inhibitory effect of these substances was neutralized by the addition of an activated plasma thromboplastin antecedent, factor XI, (PTA) fraction. Other positively charged substances including protamine, hexadimethrine, polylysine, polyornithine, methylene blue, and ortho-toluidine blue also inhibited the contact stages of coagulation, but the inhibitory effect on coagulation was not neutralized by the activated PTA fraction. Negatively charged substances such as heparin and insulin did not inhibit the contact stages of coagulation. Cytochrome c inhibited Celite adsorption of a partially purified Hageman factor fraction, and cytochrome, ribonuclease, spermine, and lysozome inhibited the adsorption of Hageman factor from PTA-deficient plasma. Very much smaller quantities of Celite completely adsorbed Hageman factor from the fraction rather than from whole plasma, which suggested the possibility that plasma contains an inhibitor or inhibitors of Hageman factor adsorption. Furthermore cytochrome c, spermine, ribonuclease, and lysozyme inhibited the coagulant activity of the following activators of the Hageman and PTA factors: Celite, kaolin, sodium stearate, ellagic acid, and skin. It is suggested that negatively charged sites on these activators are critical for adsorption and activation and that inhibition results from neutralization of the negatively charged sites by the adsorbed inhibtor. Tests with polylysine polymers indicate that inhibitory activity is directly related to molecular size over the molecular weight range of 4000 to 100,000.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5645860      PMCID: PMC297269          DOI: 10.1172/JCI105806

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  The purification of activated Hageman factor (activated factor XII).

Authors:  O D RATNOFF; E W DAVIE
Journal:  Biochemistry       Date:  1962-11       Impact factor: 3.162

2.  The interrelationship of coagulation of plasma and release of peptides.

Authors:  J MARGOLIS
Journal:  Ann N Y Acad Sci       Date:  1963-02-04       Impact factor: 5.691

3.  Hageman trait and PTA deficiency; the role of contact of blood with glass.

Authors:  J P SOULIER; O WARTELLE; D MENACHE
Journal:  Br J Haematol       Date:  1959-01       Impact factor: 6.998

4.  The role of Hageman factor in the initiation of blood coagulation.

Authors:  R M HARDISTY; J MARGOLIS
Journal:  Br J Haematol       Date:  1959-04       Impact factor: 6.998

5.  Ionic charges of glass surfaces and other materials, and their possible role in the coagulation of blood.

Authors:  D HUBBARD; G L LUCAS
Journal:  J Appl Physiol       Date:  1960-03       Impact factor: 3.531

6.  Role of Hageman factor in the initiation of clotting by glass; evidence that glass frees Hageman factor from inhibition.

Authors:  O D RATNOFF; J M ROSENBLUM
Journal:  Am J Med       Date:  1958-08       Impact factor: 4.965

Review 7.  The biology and pathology of the initial stages of blood coagulation.

Authors:  O D Ratnoff
Journal:  Prog Hematol       Date:  1966

8.  Hageman factor: alterations in physical properties during activation.

Authors:  V H Donaldson; O D Ratnoff
Journal:  Science       Date:  1965-11-05       Impact factor: 47.728

9.  Activation of factors XII (Hageman) and XI (PTA) by skin contact.

Authors:  H L Nossel
Journal:  Proc Soc Exp Biol Med       Date:  1966-05

10.  The measurement of factor XI (Plasma thromboplastin antecedent). Diagnosis and therapy of the congenital deficiency state.

Authors:  H L Nossel; J Niemetz; R S Mibashan; W G Schulze
Journal:  Br J Haematol       Date:  1966-03       Impact factor: 6.998

View more
  15 in total

1.  Inhibition of prekallikrein activation in human plasma by components of bovine plasma.

Authors:  K M Weerasinghe; E P Kirby
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

2.  Activation of Hageman factor by collagen.

Authors:  G D Wilner; H L Nossel; E C LeRoy
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

3.  Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.

Authors:  P C Harpel; M W Mosesson
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

4.  What factors determine thrombogenicity.

Authors:  L Vroman
Journal:  Bull N Y Acad Med       Date:  1972-02

Review 5.  Local and systemic factors in the pathogenesis of thrombosis.

Authors:  D Deykin
Journal:  Calif Med       Date:  1970-03

6.  Coagulation and fibrinolysis after injury.

Authors:  P T Flute
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1970

7.  A proteaselike permeability factor in guinea pig skin: contact activation of the latent permeability factor and its nature as a prekallikrein activator.

Authors:  K Kozono; T Yamamoto; T Kambara
Journal:  Am J Pathol       Date:  1980-09       Impact factor: 4.307

8.  Activation of Hageman factor and initiation of hepatic vein thrombosis in the hyperlipemic rat.

Authors:  J G Latour; C Léger; S Renaud
Journal:  Am J Pathol       Date:  1974-08       Impact factor: 4.307

9.  Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Authors:  R C Wiggins; B N Bouma; C G Cochrane; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

Authors:  C G Cochrane; S D Revak; K D Wuepper
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.